Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Teikoku Pharma USA Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is being reviewed by 1 distinct examiner within 1 distinct art unit. This level of focus indicates that the company's current active prosecution is limited to a specific technical and administrative path at the patent office.
The busiest examiner for the portfolio is HAVLIN, ROBERT H, who is currently managing 1 busiest examiner pending office action. This action represents the full extent of the company's pending workload. With only 1 distinct examiner and 1 distinct art unit involved, the prosecution strategy is entirely centered on the interaction with this one official. Practitioners should prioritize understanding the specific examination history of HAVLIN, ROBERT H to effectively resolve the 1 pending office action. The lack of other active matters suggests a targeted portfolio within this particular technology area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19338730 | TRANSDERMAL DEXMEDETOMIDINE FOR TREATING AGITATION | HAVLIN, ROBERT H | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19338730 | TRANSDERMAL DEXMEDETOMIDINE FOR TREATING AGITATION | HAVLIN, ROBERT H | 1626 | §103DP | Final Rejection | — | Pending | Sep 24, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTeikoku Pharma USA Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Robert H Havlin has the most, with 1 of Teikoku Pharma USA Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
